LISATA THERAPEUTICS, INC.

CIK 320017 LSTA·Pharmaceutical Preparations · All EDGAR filings ↗

Refine

Going concern Filing comparison 2026-04-28

LISATA THERAPEUTICS, INC.'s going-concern disclosure changed

Substantial doubt about ability to continue as a going concern → Risk-factor language only

… and other strategic arrangements, meeting our financial obligations under various licensing and other strategic arrangements, the funding of our clinical trials for product candidates, and the commercialization of the relevant technology; •our ability to build and maintain the management and human resources infrastructure necessary to support the operation and/or growth of our business; •our ability to continue as a going concern; •whether a market is established for our products and our ability to capture a meaningful share of this market; •scientific, regulatory and medical developments…

Evidence

Blank check: No
Comparable: Yes
Current state: risk_factor_only
Current state label: Risk-factor language only
Direction: eased
Located in: risk factors / forward-looking statements only
Prior filed: 2026-03-12
Prior form: 10-K
Prior state: substantial_doubt
Prior state label: Substantial doubt about ability to continue as a going concern
Source: ASC 205-40 going-concern note comparison
Why: Disclosure about the company's ability to continue as a going concern changed compared with its previous report.

Source filing ↗ Prior filing ↗

Going concern Filing comparison 2026-03-12

LISATA THERAPEUTICS, INC. disclosed substantial doubt about its ability to continue as a going concern

No going-concern disclosure → Substantial doubt about ability to continue as a going concern

As discussed in Note 1 to the consolidated financial statements, the Company has a history of net operating losses and negative cash flows from operating activities and has cash and cash equivalents of approximately $16 million as of December 31, 2025. These conditions, along with other matters as set forth in Note 1, raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this…

Evidence

Blank check: No
Comparable: Yes
Current state: substantial_doubt
Current state label: Substantial doubt about ability to continue as a going concern
Direction: escalated
Located in: going-concern note
Prior filed: 2025-02-27
Prior form: 10-K
Prior state: none
Prior state label: No going-concern disclosure
Source: ASC 205-40 going-concern note comparison
Why: Disclosure about the company's ability to continue as a going concern changed compared with its previous report.

Source filing ↗ Prior filing ↗